<DOC>
	<DOC>NCT01109056</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASISÂ®) in patients with primary pterygium (abnormal growth on surface of eye).</brief_summary>
	<brief_title>Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Have a pterygium in at least one eye that has not been previously removed with surgery Uncontrolled systemic disease Active eye disease Current or anticipated use of topical eye medications other than artificial tears. Anticipated wearing of contact lenses</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>